How I treat HER2-low advanced breast cancer
The Breast · 2023-02 · 67 · 116-123
DOI: 10.1016/j.breast.2023.01.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Breast, 2023-02. Verfasst von Ilana Schlam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Targeting low levels of human receptor epidermal growth factor 2 (HER2) expression has reshaped the treatment paradigm for half of the patients with advanced breast cancer. HER2-low is currently defined as a HER2 immunohistochemical expression of 1+ or 2+ without amplification by in-situ hybridization. Until recently, HER2-targeted agents were ineffective in treating patients with HER2-low disease. AREAS COVERED: In this narrative review, we summarize the current management of HER2-low breast cancer. We highlight the findings of the DESTINY-Breast 04 phase 3 trial, which confirmed the efficacy of trastuzumab-deruxtecan (T-DXd) for the treatment of patients with advanced, pretreated HER2-low breast cancer. We also discuss how to implement this new treatment option in treatment algorithms of hormone receptor (HR)-positive and triple-negative tumors, as well as how to optimally manage selected toxicities of T-DXd. EXPERT OPINION: T-DXd is currently the standard of care for patients with advanced, pretreated, HER2-low breast cancer. Based on the design of the DESTINY-Breast04 trial, the current optimal place in treatment algorithms is after the first line of chemotherapy, both in HR-positive and triple-negative breast cancer. Up to 10-15% of the patients receiving T-DXd are expected to develop interstitial lung disease, which in 1-2% of the cases can be fatal. Adequate monitoring and prompt management are required to minimize the impact of ILD and to safely implement T-DXd in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, University of Milan, Milan, Italy. Electronic addres…
Zitieren
APA
Schlam, I., Tolaney, S. M., & Tarantino, P. (2023). How I treat HER2-low advanced breast cancer. The Breast, 67, 116-123. https://doi.org/10.1016/j.breast.2023.01.005
Vancouver
Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. The Breast. 2023;67:116-123. doi:10.1016/j.breast.2023.01.005
BibTeX
@article{Schlam2023,
author = {Schlam, Ilana and Tolaney, Sara M and Tarantino, Paolo},
title = {How I treat HER2-low advanced breast cancer},
journal = {The Breast},
year = {2023},
volume = {67},
pages = {116--123},
doi = {10.1016/j.breast.2023.01.005}
}
EUVIMED